RT Journal Article
SR Electronic
T1 Robust SARS-CoV-2-specific and heterologous immune responses after natural infection in elderly residents of Long-Term Care Facilities
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.13.21261889
DO 10.1101/2021.08.13.21261889
A1 Tut, Gokhan
A1 Lancaster, Tara
A1 Butler, Megan S.
A1 Sylla, Panagiota
A1 Spalkova, Eliska
A1 Bone, David
A1 Kaur, Nayandeep
A1 Bentley, Christopher
A1 Amin, Umayr
A1 Jadir, Azar T.
A1 Hulme, Samuel
A1 Ayodel, Morenike
A1 Dowell, Alexander C.
A1 Pearce, Hayden
A1 Margielewska-Davies, Sandra
A1 Verma, Kriti
A1 Nicol, Samantha
A1 Begum, Jusnara
A1 Blakeway, D.
A1 Jinks, Elizabeth
A1 Tut, Elif
A1 Bruton, Rachel
A1 Krutikov, Maria
A1 Shrotri, Madhumita
A1 Giddings, Rebecca
A1 Azmi, Borscha
A1 Fuller, Chris
A1 Irwin-Singer, Aidan
A1 Hayward, Andrew
A1 Copas, Andrew
A1 Shallcross, Laura
A1 Moss, Paul
YR 2021
UL http://medrxiv.org/content/early/2021/08/18/2021.08.13.21261889.abstract
AB Long term care facilities (LTCF) provide residential and/or nursing care support for frail and elderly people and many have suffered from a high prevalence of SARS-CoV-2 infection. Although mortality rates have been high in LTCF residents there is little information regarding the features of SARS-CoV-2-specific immunity after infection in this setting or how this may influence immunity to other infections. We studied humoral and cellular immunity against SARS-CoV-2 in 152 LTCF staff and 124 residents over a prospective 4-month period shortly after the first wave of infection and related viral serostatus to heterologous immunity to other respiratory viruses and systemic inflammatory markers. LTCF residents developed high levels of antibodies against spike protein and RBD domain which were stable over 4 months of follow up. Nucleocapsid-specific responses were also elevated in elderly donors but showed waning across all populations. Antibodies showed stable and equivalent levels of functional inhibition against spike-ACE2 binding in all age groups with comparable activity against viral variants of concern. SARS-CoV-2 seropositive donors showed high levels of antibodies to other beta-coronaviruses but serostatus did not impact humoral immunity to influenza or RSV. SARS-CoV-2-specific cellular responses were equivalent across the life course but virus-specific populations showed elevated levels of activation in older donors. LTCF residents who are survivors of SARS-CoV-2 infection thus show robust and stable immunity which does not impact responses to other seasonal viruses. These findings augur well for relative protection of LTCF residents to re-infection. Furthermore, they underlie the potent influence of previous infection on the immune response to Covid-19 vaccine which may prove to be an important determinant of future vaccine strategy.One sentence summery Care home residents show waning of nucleocapsid specific antibodies and enhanced expression of activation markers on SARS-CoV-2 specific cellsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementUK Government Department of Health and Social Care. The funder had no role in the study design, data collection, data analysis, data interpretation or writing of the report. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from the South Central - Hampshire B Research Ethics Committee, REC Ref: 20/SC/0238All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified test results and limited meta-data will be made available for use by researchers in future studies, subject to appropriate research ethical approvals, once the VIVALDI study cohort has been finalised. These datasets will be accessible via the Health Data Research UK Gateway https://www.healthdatagateway.org/.